Agios appoints Brian Goff as CEO; Jackie Fouse transitions to Chair effective Aug 8, 2022

AGIOS PHARMACEUTICALS, INC.

CEO Brian Goff appointed effective Aug 8, 2022; current CEO Jackie Fouse becomes Chair of Board.
Goff receives $775K base salary, 70% target bonus, equity grants: $9M options, $5M PSUs, $2M RSUs.
Goff also gets $250K relocation payment; equity awards vest over 3–4 years under Nasdaq inducement grant.
Fouse's unvested equity continues to vest; she will not receive director equity awards in 2022.
Former chair David Schenkein remains on board as director.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Jacqualyn A. Fouse

Chair of the Board

AGIO · AGIOS PHARMACEUTICALS, INC.

Effective: 2022-08-08
Successor: Brian Goff
Filed: July 12, 2022, 7:59 PM ET

Jacqualyn A. Fouse, Ph.D. will resign from the position of Chief Executive Officer and will assume the role of Chair of the Board of Directors

Appointed

Brian Goff

Chief Executive Officer

AGIO · AGIOS PHARMACEUTICALS, INC.

Effective: 2022-08-08
Filed: July 12, 2022, 7:59 PM ET

the Board appointed Brian Goff as the Company’s Chief Executive Officer and as a member of the Board

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jacqualyn A. Fouse changed role as Chair of the Board at AGIOS PHARMACEUTICALS, INC..

Action: assume the role of
Role: Chair of the Board

Exact text from the filing

Jacqualyn A. Fouse, Ph.D. will resign from the position of Chief Executive Officer and will assume the role of Chair of the Board of Directors

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Brian Goff was appointed as Chief Executive Officer at AGIOS PHARMACEUTICALS, INC..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

the Board appointed Brian Goff as the Company’s Chief Executive Officer and as a member of the Board

View on SEC.gov

AGIOS PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-22-192006

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.